Upper Tract Urothelial Carcinomas
Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BridgeBio PharmaInfigratinib
Clinical Trials (1)
Total enrollment: 39 patients across 1 trials
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Start: Mar 2020Est. completion: Feb 202339 patients
Phase 3Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
8m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
8m ago
Office Administrator
SystImmune
8m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
19m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
22m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
22m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space